Recent Advances in the Treatment
and Management of NASH
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2020 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive
This activity is valid from June 1, 2020 to
June 1, 2021
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation, and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post-test to receive continuing education credits.
If you do not pass the post-test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post-test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by an
educational grant from
Nonalcoholic fatty liver disease (NAFLD) is a progressive spectrum
of liver disorders that includes among its more severe forms
nonalcoholic steatohepatitis (NASH). NASH is one of the most common
causes of chronic liver disease worldwide, affecting an estimated
25% of the world's population. The disease can be characterized as
inflammation of the liver and the damage caused by a buildup of fat
in the liver and may worsen, causing scarring of the liver which can
lead to cirrhosis. Closely associated with rising rates of obesity
and metabolic syndrome, the prevalence of these conditions continues
to increase creating a clinical and economic burden. NASH can lead
to significant morbidity and mortality, including liver fibrosis and
cirrhosis. NASH remains underdiagnosed and undertreated as patients
may have no symptoms at all which makes it hard to diagnosis. As
NASH continues to progress and the liver damage gets worse, patients
may experience fatigue, weight loss, overall weakness and an ache in
the upper right part of the belly.
Fatty liver disease and advanced forms of fibrosis have limited
treatment options. The first line of treatment at this time is
usually weight loss through a combination of a healthy diet and
exercise. For those who have cirrhosis due to nonalcoholic
steatohepatitis, liver transplantation may be an option. Outcomes of
liver transplant in this population group are generally very good.
NASH, described as the hepatic manifestation of metabolic syndrome,
remains challenging to diagnose and treat, but significant advances
have been made in the recent years. There are several agents that
are on the horizon and still more that are in clinical trials that
look promising to help treat this growing disease.
Upon completion of this
activity, participants will be able to:
Discuss the pathogenesis and the
pathophysiologic mechanisms for NAFLD and NASH
Assess the current guidelines and
recommendations for appropriate diagnostic and treatment
strategies of NAFLD and NASH in order to optimize proper
Identify current assessment and
diagnostic tools for NASH and their value in predicting patient
Analyze the efficacy and safety
profiles of emerging treatments for NASH to achieve
individualized treatment goals
Explore the challenges and
opportunities in NASH disease management, including patient
adherence, quality of life and total cost of care
||Romina Lomonaco, MD
Assistant Professor of Medicine
Division of Endocrinology
Diabetes and Metabolism
The University of Florida
Lomonaco has no relevant financial relationships to
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by
an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue